2026 predictions: historic FDA shift, plausible mechanisms, bespoke tx, RFK Jr., biotechs, state AGs, peptides, embryos The Niche BPC 157: The peptide with big claims and scant evidence STAT The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner FDA's Overreach on Compounded Peptides